216 related articles for article (PubMed ID: 12576434)
1. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
Ayyoub M; Zippelius A; Pittet MJ; Rimoldi D; Valmori D; Cerottini JC; Romero P; Lejeune F; Liénard D; Speiser DE
Clin Cancer Res; 2003 Feb; 9(2):669-77. PubMed ID: 12576434
[TBL] [Abstract][Full Text] [Related]
2. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
4. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
[TBL] [Abstract][Full Text] [Related]
5. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
6. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V; Speiser DE; Rufer N; Reynard S; Barbey C; Cerottini JC; Leyvraz S; Pinilla C; Romero P
Eur J Immunol; 2006 Jul; 36(7):1805-14. PubMed ID: 16761313
[TBL] [Abstract][Full Text] [Related]
7. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
Speiser DE; Liénard D; Rufer N; Rubio-Godoy V; Rimoldi D; Lejeune F; Krieg AM; Cerottini JC; Romero P
J Clin Invest; 2005 Mar; 115(3):739-46. PubMed ID: 15696196
[TBL] [Abstract][Full Text] [Related]
8. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
9. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
10. An antigen-targeted approach to adoptive transfer therapy of cancer.
Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
[TBL] [Abstract][Full Text] [Related]
11. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
[TBL] [Abstract][Full Text] [Related]
12. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
Liénard D; Rimoldi D; Marchand M; Dietrich PY; van Baren N; Geldhof C; Batard P; Guillaume P; Ayyoub M; Pittet MJ; Zippelius A; Fleischhauer K; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2004 May; 4():4. PubMed ID: 15149168
[TBL] [Abstract][Full Text] [Related]
14. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.
Larrieu P; Renaud V; Godet Y; Jotereau F; Fonteneau JF
Cancer Immunol Immunother; 2008 May; 57(5):745-52. PubMed ID: 18097665
[TBL] [Abstract][Full Text] [Related]
15. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
16. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
18. Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.
Chapatte L; Colombetti S; Cerottini JC; Lévy F
Cancer Res; 2006 Jan; 66(2):1155-60. PubMed ID: 16424053
[TBL] [Abstract][Full Text] [Related]
19. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.
Palermo B; Del Bello D; Sottini A; Serana F; Ghidini C; Gualtieri N; Ferraresi V; Catricalà C; Belardelli F; Proietti E; Natali PG; Imberti L; Nisticò P
Cancer Res; 2010 Sep; 70(18):7084-92. PubMed ID: 20823160
[TBL] [Abstract][Full Text] [Related]
20. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]